. Author manuscript; available in PMC: 2017 Jun 5.

Published in final edited form as: J Infect Chemother. 2015 Jun 9;21(9):663–667. doi: 10.1016/j.jiac.2015.05.011

Table 1.

Patient characteristics

Characteristics	Number of Patients

Median age (range), yr	65 (34–78)

Male sex, n(%)	9 (45)

Diagnosis, n(%)
AML, induction	19 (95)
AML, relapse	1 (5)

Chemotherapy, n(%)
Cytarabine-containing regimen	9 (45)
Clofarabine-containing regimen	8 (40)
Miscellaneous^*	3 (20)

AZD1152 (an experimental aurora kinase inhibitor) alone (n=1) or in combination with low-dose cytarabine (n=2)